Journal of Oncology · 2019 · 48 citations · 26 references
MedicineCancer BiologyOncologyCarcinogenesisMetastasisNeoplasiaCancer Cell SignalingOncogenic Signaling PathwaysPancreatic CancerRas Family OncogenesSignal Transduction In CancerKras-targeted TherapyMolecular Drug ResistancePull-down AssaysRas Resistance MechanismsRas Signaling ActivationRas-driven TumorigenesisRas-targeted TherapiesTherapeutic Resistance Mechanisms
Oncogenic KRAS mutation plays a key role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis with nearly 95% of PDAC harboring mutation-activated KRAS, which has been considered an undruggable target. Doublecortin-like kinase 1 (DCLK1) is often overexpressed in pancreatic cancer, and recent studies indicate that DCLK1+ PDAC cells can initiate pancreatic tumorigenesis. In this study, we investigate whether overexpressing DCLK1 activates RAS and promotes tumorigenesis, metastasis, and drug resistance. Human pancreatic cancer cells (AsPC-1 and MiaPaCa-2) were infected with lentivirus and selected to create stable DCLK1 isoform 2 (alpha-long, AL) overexpressing lines. The invasive potential of these cells relative to vector control was compared using Matrigel coated transwell assay. KRAS activation and interaction were determined by a pull-down assay and coimmunoprecipitation. Gemcitabine, mTOR (Everolimus), PI3K (LY-294002), and BCL-2 (ABT-199) inhibitors were used to evaluate drug resistance downstream of KRAS activation. Immunostaining of a PDAC tissue microarray was performed to detect DCLK1 alpha- and beta-long expression. Analysis of gene expression in human PDAC was performed using the TCGA PAAD dataset. The effects of targeting DCLK1 were studied using xenograft and Pdx<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:msup><mml:mrow><mml:mn mathvariant="normal">1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math>Kra<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">G</mml:mi><mml:mn mathvariant="normal">12</mml:mn><mml:mi mathvariant="normal">D</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math>Trp5<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mrow><mml:msup><mml:mrow><mml:mn mathvariant="normal">3</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mn mathvariant="normal">172</mml:mn><mml:mi mathvariant="normal">H</mml:mi><mml:mo>/</mml:mo><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math> (KPC) mouse models. Overexpression of DCLK1-AL drives a more than 2-fold increase in invasion and drug resistance and increased the activation of KRAS. Evidence from TCGA PAAD demonstrated that human PDACs expressing high levels of DCLK1 correlate with activated PI3K/AKT/MTOR-pathway signaling suggesting greater KRAS activity. High DCLK1 expression in normal adjacent tissue of PDAC correlated with poor survival and anti-DCLK1 mAb inhibited pancreatic tumor growth in vivo in mouse models.
26
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Tissue-based map of the human proteome
Mathias Uhlén, Linn Fagerberg, Björn M. Hallström et al. · Science · 2015 · 15.9K citations · Full text
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones, D. Williams Parsons, Jimmy Lin et al. · Science · 2008 · 4K citations · Full text
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell, Marina Pajic, Ann‐Marie Patch et al. · Nature · 2015 · 2.7K citations · Full text
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim, Emily T. Mirek, Nicole M. Aiello et al. · Cell · 2012 · 2.1K citations · Full text
Medicine, Cancer Biology, Oncology +12